PET Imaging

Jun. 24, 2025 — GE HealthCare has announced that the U.S. Food and Drug Administration (FDA) approved an updated label for its positron emission tomography (PET) imaging agent Vizamyl (flutemetamol F 18 injection) for beta-amyloid detection.

June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a physics company transforming the production of radioisotopes, have announced the signing of a letter of intent to provide dGenThera with access to high‑purity astatine‑211 (At‑211

June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging solutions will be on display at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana.

June 19, 2025 — Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine — with one of the key intentions being the development and research of innovative total body PET/CT technology.i This effort is ex

Oct. 21, 2024 — Siemens Healthineers recently received Food and Drug Administration clearance for two new features in its syngo.PET Cortical Analysis software application that use positron emission tomography (PET) to measure protein deposits in the brain associated with Alzheimer’s disease.